Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,363,515
  • Shares Outstanding, K 80,497
  • Annual Sales, $ 250,650 K
  • Annual Income, $ -344,870 K
  • 60-Month Beta 1.49
  • Price/Sales 21.74
  • Price/Cash Flow N/A
  • Price/Book 102.21
Trade APLS with:

Options Overview

Details
  • Implied Volatility 100.85%
  • Historical Volatility 43.92%
  • IV Percentile 99%
  • IV Rank 69.00%
  • IV High 123.15% on 05/14/21
  • IV Low 51.21% on 11/13/20
  • Put/Call Vol Ratio 0.58
  • Today's Volume 498
  • Volume Avg (30-Day) 2,165
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 67,808
  • Open Int (30-Day) 59,786

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -1.70
  • Number of Estimates 8
  • High Estimate -1.58
  • Low Estimate -1.97
  • Prior Year -1.57
  • Growth Rate Est. (year over year) -8.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.41 +10.30%
on 07/15/21
73.00 -8.73%
on 07/02/21
+3.18 (+5.01%)
since 06/29/21
3-Month
43.57 +52.93%
on 05/14/21
73.00 -8.73%
on 07/02/21
+18.39 (+38.12%)
since 04/29/21
52-Week
25.49 +161.40%
on 07/31/20
73.00 -8.73%
on 07/02/21
+39.49 (+145.50%)
since 07/29/20

Most Recent Stories

More News
New genomics funding to meet environmental challenges

COMTEX_390625482/2669/2021-07-29T15:16:12

APLS : 66.63 (-1.58%)
Why Apellis (APLS) Might Surprise This Earnings Season

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

APLS : 66.63 (-1.58%)
Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss...

APLS : 66.63 (-1.58%)
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange...

APLS : 66.63 (-1.58%)
Pan-Canadian team to lead national project to analyze and create standards for environmental DNA

COMTEX_390300402/2669/2021-07-23T11:30:29

APLS : 66.63 (-1.58%)
Canadian genomics team joins international initiative to study and protect global biodiversity

COMTEX_390245209/2669/2021-07-22T11:00:35

APLS : 66.63 (-1.58%)
Worldwide Peptide Therapeutics Industry to 2030 - Featuring Apellis Pharmaceuticals, Eli Lilly and Novo Nordisk Among Others

The "Peptide Therapeutics Market by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area: Industry Trends and Global Forecasts, 2021 - 2030" report has been added...

APLS : 66.63 (-1.58%)
LLY : 245.33 (-0.48%)
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements...

APLS : 66.63 (-1.58%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to one new employee...

APLS : 66.63 (-1.58%)
Centennial College receives $2 million in NSERC grants to support local retailers

COMTEX_389411074/2669/2021-07-06T08:01:00

APLS : 66.63 (-1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the...

See More

Key Turning Points

3rd Resistance Point 72.03
2nd Resistance Point 70.82
1st Resistance Point 68.72
Last Price 66.63
1st Support Level 65.41
2nd Support Level 64.20
3rd Support Level 62.10

See More

52-Week High 73.00
Last Price 66.63
Fibonacci 61.8% 54.85
Fibonacci 50% 49.24
Fibonacci 38.2% 43.64
52-Week Low 25.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar